The Impact of Interleukin 28b Gene Polymorphism on the Virological Response to Combined Pegylated Interferon and Ribavirin Therapy in Chronic HCV Genotype 4 Infected Egyptian Patients Using Data Mining Analysis
To Cite:
Khairy
M, Fouad
R, Mabrouk
M, El-Akel
W, Bakr Awad
A, et al. The Impact of Interleukin 28b Gene Polymorphism on the Virological Response to Combined Pegylated Interferon and Ribavirin Therapy in Chronic HCV Genotype 4 Infected Egyptian Patients Using Data Mining Analysis,
Hepat Mon.
2013
; 13(7):e10509.
doi: 10.5812/hepatmon.10509.
1.
Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29 Suppl 1: 74-81[DOI][PubMed]
2.
El-Raziky MS,
El-Hawary M,
Esmat G,
Abouzied AM,
El-Koofy N,
Mohsen N,
et al.
Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children. World J Gastroenterol. 2007; 13(12): 1828-32[PubMed]
3.
Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis. 2000; 182(3): 698-707[DOI][PubMed]
4.
Lyra AC, Ramrakhiani S, Bacon BR, Di Bisceglie AM. Infection with hepatitis C virus genotype 4 in the United States. J Clin Gastroenterol. 2004; 38(1): 68-71[PubMed]
5.
Payan C,
Roudot-Thoraval F,
Marcellin P,
Bled N,
Duverlie G,
Fouchard-Hubert I,
et al.
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat. 2005; 12(4): 405-13[DOI][PubMed]
6.
van Asten L,
Verhaest I,
Lamzira S,
Hernandez-Aguado I,
Zangerle R,
Boufassa F,
et al.
Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis. 2004; 189(2): 292-302[DOI][PubMed]
7.
El-Zayadi AR,
Attia M,
Barakat EM,
Badran HM,
Hamdy H,
El-Tawil A,
et al.
Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol. 2005; 100(11): 2447-52[DOI][PubMed]
8.
Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int. 2011; 31 Suppl 1: 45-52[DOI][PubMed]
9.
Asselah T,
Estrabaud E,
Bieche I,
Lapalus M,
De Muynck S,
Vidaud M,
et al.
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010; 30(9): 1259-69[DOI][PubMed]
10.
Ge D,
Fellay J,
Thompson AJ,
Simon JS,
Shianna KV,
Urban TJ,
et al.
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401[DOI][PubMed]
11.
Huang CF,
Huang JF,
Yang JF,
Hsieh MY,
Lin ZY,
Chen SC,
et al.
Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol. 2012; 56(1): 34-40[DOI][PubMed]
12.
Rauch A,
Kutalik Z,
Descombes P,
Cai T,
Di Iulio J,
Mueller T,
et al.
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4): 1338-45, 45 e1-7[DOI][PubMed]
13.
Khattab MA,
Ferenci P,
Hadziyannis SJ,
Colombo M,
Manns MP,
Almasio PL,
et al.
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol. 2011; 54(6): 1250-62[DOI][PubMed]
14.
Langhans B,
Kupfer B,
Braunschweiger I,
Arndt S,
Schulte W,
Nischalke HD,
et al.
Interferon-lambda serum levels in hepatitis C. J Hepatol. 2011; 54(5): 859-65[DOI][PubMed]
15.
Kurosaki M,
Matsunaga K,
Hirayama I,
Tanaka T,
Sato M,
Yasui Y,
et al.
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res. 2010; 40(4): 251-60[DOI][PubMed]
16.
Kurosaki M,
Sakamoto N,
Iwasaki M,
Sakamoto M,
Suzuki Y,
Hiramatsu N,
et al.
Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol. 2011; 46(3): 401-9[DOI][PubMed]
17.
Izumi N, Asahina Y, Kurosaki M. Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat. 2010; 2010: 703602[DOI][PubMed]
18.
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24(2): 289-93[DOI][PubMed]
19.
Olshen L, Breiman JH, Friedman RA, Stone Charles J. Classification and Regression Trees. 1984;
20.
Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002; 36(5 Suppl 1)-9[DOI][PubMed]
21.
Esmat G,
Abouzied A,
Mohamed MK,
et al.
Treatment with Peg Interferon alpha 2-b (PEC INF) plus ribavirin compared to Interferon alpha-2b (INF alfa-2b) plus Ribavirin on subjects with chronic hepatitis C infected with HCV genotype 4. Hepatol Res. 2002; 36(4)
22.
Hasan F,
Asker H,
Al-Khaldi J,
Siddique I,
Al-Ajmi M,
Owaid S,
et al.
Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol. 2004; 99(9): 1733-7[DOI][PubMed]
23.
Moucari R,
Ripault MP,
Martinot-Peignoux M,
Voitot H,
Cardoso AC,
Stern C,
et al.
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut. 2009; 58(12): 1662-9[DOI][PubMed]
24.
Kamal SM,
El Kamary SS,
Shardell MD,
Hashem M,
Ahmed IN,
Muhammadi M,
et al.
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology. 2007; 46(6): 1732-40[DOI][PubMed]
25.
Gad RR,
Males S,
El Makhzangy H,
Shouman S,
Hasan A,
Attala M,
et al.
Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int. 2008; 28(8): 1112-9[DOI][PubMed]
26.
Asselah T,
De Muynck S,
Broet P,
Masliah-Planchon J,
Blanluet M,
Bieche I,
et al.
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol. 2012; 56(3): 527-32[DOI][PubMed]
27.
De Nicola S,
Aghemo A,
Rumi MG,
Galmozzi E,
Valenti L,
Soffredini R,
et al.
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology. 2012; 55(2): 336-42[DOI][PubMed]
28.
Al Ashgar H,
Helmy A,
Khan MQ,
Al Kahtani K,
Al Quaiz M,
Rezeig M,
et al.
Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med. 2009; 29(1): 4-14[PubMed]
29.
Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem. 2009; 284(31): 20869-75[DOI][PubMed]
30.
Males S,
Gad RR,
Esmat G,
Abobakr H,
Anwar M,
Rekacewicz C,
et al.
Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. Antivir Ther. 2007; 12(5): 797-803[PubMed]
31.
Akuta N,
Suzuki F,
Kawamura Y,
Yatsuji H,
Sezaki H,
Suzuki Y,
et al.
Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2007; 79(11): 1686-95[DOI][PubMed]
32.
Chen TM,
Huang PT,
Tsai MH,
Lin LF,
Liu CC,
Ho KS,
et al.
Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol. 2007; 22(5): 669-75[DOI][PubMed]
33.
Abdoul H, Mallet V, Pol S, Fontanet A. Serum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotype. PLoS One. 2008; 3(6)[DOI][PubMed]
34.
Khairy M,
Abdel-Rahman M,
El-Raziky M,
El-Akel W,
Zayed N,
Khatab H,
et al.
Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup. Hepat Mon. 2012; 12(11)[DOI][PubMed]
35.
Shiratori Y, Omata M. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course? J Gastroenterol Hepatol. 2000; 15 Suppl-51[PubMed]
36.
Ciesla A,
Bociaga-Jasik M,
Sobczyk-Krupiarz I,
Glowacki MK,
Owczarek D,
Cibor D,
et al.
IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C. World J Gastroenterol. 2012; 18(35): 4892-7[DOI][PubMed]
37.
Thomas DL,
Thio CL,
Martin MP,
Qi Y,
Ge D,
O'Huigin C,
et al.
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265): 798-801[DOI][PubMed]
38.
El-Awady MK,
Mostafa L,
Tabll AA,
Abdelhafez TH,
Bader El Din NG,
Zayed N,
et al.
Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 Patients to End Stage Liver Disease. Hepat Mon. 2012; 12(4): 271-7[DOI][PubMed]
39.
McCarthy JJ,
Li JH,
Thompson A,
Suchindran S,
Lao XQ,
Patel K,
et al.
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010; 138(7): 2307-14[DOI][PubMed]
40.
Marabita F,
Aghemo A,
De Nicola S,
Rumi MG,
Cheroni C,
Scavelli R,
et al.
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology. 2011; 54(4): 1127-34[DOI][PubMed]
41.
Fabris C,
Falleti E,
Cussigh A,
Bitetto D,
Fontanini E,
Bignulin S,
et al.
IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011; 54(4): 716-22[DOI][PubMed]
42.
Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology. 2008; 47(4): 1371-83[DOI][PubMed]
43.
Kurosaki M,
Sakamoto N,
Iwasaki M,
Sakamoto M,
Suzuki Y,
Hiramatsu N,
et al.
Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. J Med Virol. 2011; 83(3): 445-52[DOI][PubMed]
Readers' Comments